Who is sponsoring NCT04783675?

NCT04783675 is sponsored by Children's Hospital of Fudan University.

What drugs are being tested in NCT04783675?

Interventions in NCT04783675: Rituximab.

What condition does NCT04783675 study?

NCT04783675 studies Steroid-Sensitive Nephrotic Syndrome.

Is NCT04783675 still recruiting?

NCT04783675 is currently completed. Last updated 11 July 2023.

Last reviewed 2023-07-11 · How we verify

NCT04783675: RTXFIRPedINS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Completed Phase 2 Last updated 11 July 2023

What this trial tests

Phase 2 trial testing Rituximab in Steroid-Sensitive Nephrotic Syndrome in 44 participants. Completed in 17 January 2023.

Timeline

13 April 2021

Primary endpoint
17 January 2023

17 January 2023

Quick facts

Lead sponsor	Children's Hospital of Fudan University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	13 April 2021
Primary completion	17 January 2023
Estimated completion	17 January 2023
Sites	8 locations across China

Drugs / interventions tested

Rituximab — full drug profile →

Conditions studied

Steroid-Sensitive Nephrotic Syndrome — all drugs for Steroid-Sensitive Nephrotic Syndrome →

Sponsor

Children's Hospital of Fudan University

Who can join

Adults 1 to 18, any sex, with Steroid-Sensitive Nephrotic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to demonstrate, from the initial episode of nephrotic syndrome (NS) in children with standard prednisolone treatment, once complete remission has occurred, that the use of Rituximab (a single intravenous infusion of 375 mg/m2) may reduce the risk of subsequent relapse during 12-month of follow-up.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.
Liu J, Deng F, Wang X, Liu C, et al · · 2024 · cited 9× · PMID 38707815 · DOI 10.1016/j.ekir.2024.02.1395
Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.
Liu J, Shen Q, Xie L, Wang J, et al · · 2022 · cited 4× · PMID 36223961 · DOI 10.1136/bmjopen-2022-064216
Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.
Jin Y, Xie Y, Fu H, Liu F, et al · · 2025 · cited 2× · PMID 41007627 · DOI 10.3390/biomedicines13092063

Verify or expand the search:

Other trials of Rituximab

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting

Other recruiting trials for Steroid-Sensitive Nephrotic Syndrome

Currently open trials in the same condition.

NCT05786768 — Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syn · Phase 2, PHASE3 · recruiting
NCT06065852 — National Registry of Rare Kidney Diseases · recruiting

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

NCT04955821 — Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS · not yet recruiting
NCT05862688 — A Cohort Study on Anti-microbial Stewardship in PICU · not yet recruiting
NCT05595239 — Blood Purification in Septic Children · NA · not yet recruiting
NCT07325903 — Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty · EARLY_PHASE1 · not yet recruiting
NCT07141615 — Clinical Observation of Qingwei Huazhuo Decoction (Product: Jinsaiyu) in Improving Children With Precocious Puberty of P · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04783675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Fudan University
Last refreshed: 11 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04783675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing